PIER(LUIGI(ZINZANI((BOLOGNA)(
(
RELAPSED(DISEASE(
(
Case(1(–(Hodgkin(Lymphoma(
This! is! the! story! of! a! 22! year>old! woman! who! received! a! diagnosis! of! Hodgkin! lymphoma,!
stage! IIB! (with! fever! and! mediastinal! bulk)! according! to! Ann! Arbor,! in! 2007.! She! received!
induction! therapy! with! ABVD,! with! unsatisfactory! response! at! interim! PET! scan.! For! this!
reason,! she! was! shifted! to! BEACOPP! and! then! to! an! ifosfamide>containing! (IEV)! regimen!
because!of!disease!progression.!She!was!able!to!mobilize!and!harvest!peripheral!blood!stem!
cells,! so! she! could! consolidate! the! post>IEV! disease! stability! with! an! autologous! stem! cell!
transplantation!(ASCT,!October!2007).!She!achieved!her!first!complete!remission!after!ASCT.!
Disease! relapse! was! documented! 15! months! later:! the! patient! then! received! brentuximab!
vedotin! (16! cycles),! with! an! initial! complete! response! but! a! late! disease! progression.!
Retreatment! with! brentuximab! vedotin! was! performed! (March! to! September! 2011),! this!
time!with!a!complete!response.!
Disease! reappeared! 14! months! later.! She! was! then! treated! with! bendamustine,! 6! cycles,!
with!a!new!complete!response!(until!September!2013).!The!duration!of!response!was!rather!
short!(9!months),!so!a!new!treatment!line!with!pembrolizumab!was!required.!Most!of!the!
lesions! disappeared! while! she! received! pembrolizumab,! although! some! new! mediastinal!
PET>positive! findings! appeared! during! the! period! of! treatment! and! were! not! judged!
consistent! with! pseudoprogression.! For! this! reason,! a! brief! treatment! with! pegilated!
liposomal! doxorubicin! was! administered! between! August! and! October! 2015,! obtaining! a!
completely!negative!PET!scan.!The!patien!received!allogeneic!transplantation!in!November!
2015.!She!is!now!well!and!in!continuous!complete!response.!!
!R
eferences:(
Chen! R,! et! al.! Five>year! survival! and! durability! results! of! brentuximab! vedotin! in! patients! with!
relapsed!or!refractory!Hodgkin!lymphoma.!Blood,!2016;!128:!1562>1566.!
!
Chen! R,! et! al.! Pembrolizumab! in! relapsed! or! refractory! Hodgkin! lymphoma:! 2>year! follow>up! of!
KEYNOTE>087.!Blood,!2019;!134:!1144>1153.(
(
Pellegrini!C,!et!al.!Italian!real!life!experience!with!brentuximab!vedotin:!results!Oncotarget,!2017;!8:!
91703>91710.!
!
Younes!A,!et!al.!Results!of!a!pivotal!phase!II!study!of!brentuximab!vedotin!for!patients!with!relapsed!
or!refractory!Hodgkin’s!lymphoma.!J!Clin!Oncol,!2012;!30:!2183>2189.!
! (
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES